Combination benefit of cognitive rehabilitation plus donepezil for Alzheimer's disease patients

Geriatrics and Gerontology International

Volumn 16, Issue 2, 2016, Pages 200-204

  Matsuzono, Kosuke ^a,b   Hishikawa, Nozomi ^a   Takao, Yoshiki ^b   Wakutani, Yosuke ^b   Yamashita, Toru ^a   Deguchi, Kentaro ^a   Abe, Koji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Kurashiki Heisei Hospital   (Japan)

Author keywords

Alzheimer's disease; Cognitive function; Cognitive rehabilitation; Dementia; Donepezil

Indexed keywords

DONEPEZIL; CHOLINESTERASE INHIBITOR; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

ALZHEIMER DISEASE; ARTICLE; COGNITIVE REHABILITATION; CONTROLLED STUDY; DISEASE SEVERITY; HUMAN; MAJOR CLINICAL STUDY; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL THERAPY; PHYSIOTHERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPEECH THERAPY; TREATMENT OUTCOME; AGED; COGNITIVE THERAPY; MULTIMODALITY CANCER THERAPY; SEVERITY OF ILLNESS INDEX;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; HUMANS; INDANS; PIPERIDINES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84956794395     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/ggi.12455     Document Type: Article

References (24)

1. Burns A, Rossor M, Hecker J etal. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237-244.
2. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998; 50: 136-145.
3. Raskind MA, Peskind ER, Wessel T, Yuan W, Grp GU-S. Galantamine in AD - a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000; 54: 2261-2268.
4. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001; 71: 589-595.
5. Tariot PN, Farlow MR, Grossberg GT etal. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291: 317-324.
6. Bullock R, Touchon J, Bergman H etal. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005; 21: 1317-1327.
7. Dysken MW, Sano M, Asthana S etal. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA 2014; 311: 33-44.
8. Kukull WA, Ganguli M. Epidemiology of dementia - concepts and overview. Neurol Clin 2000; 18: 923-950.
9. Galante E, Venturini G, Fiaccadori C. Computer-based cognitive intervention for dementia: preliminary results of a randomized clinical trial. G Ital Med Lav Ergon 2007; 29: B26-B32.
10. DeVreese LP, Neri M, Boiardi R, Ferrari P, Belloi L, Salvioli G. Memory training and drug therapy act differently on memory and metamemory functioning: evidence from a pilot study. Arch Gerontol Geriatr 1996; 22 (Suppl. 1): 9-22.
11. Petersen RC, Thomas RG, Grundman M etal. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352: 2379-2388.
12. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging 2008; 3: 211-225.
13. Papez JW. A proposed mechanism of emotion. 1937. J Neuropsychiatry Clin Neurosci 1995; 7: 103-112.
14. Penfield W, Perot P. The brain's record of auditory and visual experience. A final summary and discussion. Brain 1963; 86: 595-696.
15. McFie J, Zangwill OL. Visual-constructive disabilities associated with lesions of the left cerebral hemisphere. Brain 1960; 83: 243-260.
16. Benson DF, Barton MI. Disturbances in constructional abilities. Cortex 1970; 6: 19-46.
17. McGaugh JL, Roozendaal B. Role of adrenal stress hormones in forming lasting memories in the brain. Curr Opin Neurobiol 2002; 12: 205-210.
18. Dolan RJ, Lane R, Chua P, Fletcher P. Dissociable temporal lobe activations during emotional episodic memory retrieval. Neuroimage 2000; 11: 203-209.
19. Quayhagen MP, Quayhagen M, Corbeil RR etal. Coping with dementia: evaluation of four nonpharmacologic interventions. Int Psychogeriatr 2000; 12: 249-265.
20. Davis RN, Massman PJ, Doody RS. Cognitive intervention in Alzheimer disease: a randomized placebo-controlled study. Alzheimer Dis Assoc Disord 2001; 15: 1-9.
21. Cahn-Weiner DA, Malloy PF, Rebok GW, Ott BR. Results of a Randomized placebo-controlled study of memory training for mildly impaired Alzheimer's disease patients. Appl Neuropsychol 2003; 10: 215-223.
22. Loewenstein DA, Acevedo A, Czaja SJ, Duara R. Cognitive rehabilitation of mildly impaired Alzheimer disease Patients on cholinesterase inhibitors. Am J Geriatr Psychiatry 2004; 12: 395-402.
23. Neely AS, Vikstrom S, Josephsson S. Collaborative memory intervention in dementia: caregiver participation matters. Neuropsychol Rehabil 2009; 19: 696-715.
24. Clare L, Linden DE, Woods RT etal. Goal-oriented cognitive rehabilitation for people with early-stage Alzheimer disease: a single-blind randomized controlled trial of clinical efficacy. Am J Geriatr Psychiatry 2010; 18: 928-939.